FDA Grants Accelerated Approval to Takeda's Iclusig for Ph-Positive Acute Lymphoblastic Leukemia

Label expansion approval for Iclusig (ponatinib) addresses adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Source link
#FDA #Grants #Accelerated #Approval #Takeda039s #Iclusig #PhPositive #Acute #Lymphoblastic #Leukemia